<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of celiac disease in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of celiac disease in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of celiac disease in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Stahl, MD, MSCS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edwin Liu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H477989349"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Celiac disease, also known as gluten-sensitive enteropathy or celiac sprue, is a common immune-mediated inflammatory disease of the small intestine caused by an autoimmune response to dietary gluten and related proteins in genetically predisposed individuals. It differs from food allergies, which are mediated by immunoglobulin (Ig) E or non-IgE (T cell) mechanisms. For patients with a confirmed diagnosis of celiac disease, the cornerstone of treatment is a lifelong gluten-free diet [<a href="#rid1">1-5</a>].</p><p>The diagnosis of celiac disease in children is discussed here. Other aspects of celiac disease in children are discussed in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">"Management of celiac disease in children"</a>.)</p><p></p><p class="headingAnchor" id="H477986227"><span class="h1">INDICATIONS FOR TESTING</span><span class="headingEndMark"> — </span>Testing for celiac disease is recommended for patients with suggestive symptoms and also for children in groups at increased risk for having the disease, regardless of symptoms  (<a class="graphic graphic_table graphicRef50751" href="/z/d/graphic/50751.html" rel="external">table 1</a>), provided that they are on a gluten-containing diet [<a href="#rid1">1,5-7</a>]:</p><p class="headingAnchor" id="H477994561"><span class="h2">Patients with symptoms suggesting celiac disease</span><span class="headingEndMark"> — </span>We suggest testing patients with any symptoms and signs suggestive of celiac disease. These may include classical gastrointestinal symptoms, nonspecific behavioral symptoms, and/or extraintestinal manifestations. Decisions about diagnostic testing should be based on symptoms, signs, and risk factors, without regard to the individual's country of origin, ancestry or race/ethnicity. </p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal symptoms (see  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on '"Classical" gastrointestinal symptoms'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal bloating/distension</p><p class="bulletIndent2"><span class="glyph">•</span>Poor weight gain/weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Constipation</p><p class="bulletIndent2"><span class="glyph">•</span>Vomiting</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extraintestinal manifestations  (<a class="graphic graphic_table graphicRef76474 graphicRef71271" href="/z/d/graphic/76474.html" rel="external">table 2A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Non-gastrointestinal manifestations'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic and behavioral symptoms such as headaches, difficulty concentrating, or irritability</p><p class="bulletIndent2"><span class="glyph">•</span>Arthritis or arthralgias (even if there is a presumed underlying rheumatic disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal liver biochemical tests</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic fatigue</p><p class="bulletIndent2"><span class="glyph">•</span>Short stature or low height velocity</p><p class="bulletIndent2"><span class="glyph">•</span>Pubertal delay</p><p class="bulletIndent2"><span class="glyph">•</span>Iron deficiency anemia often poorly responsive to supplementation</p><p class="bulletIndent2"><span class="glyph">•</span>Dermatitis herpetiformis-like rash  (<a class="graphic graphic_picture graphicRef70783 graphicRef139241" href="/z/d/graphic/70783.html" rel="external">picture 1A-B</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Dental enamel hypoplasia of permanent teeth (symmetric distribution)</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent aphthous stomatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Osteopenia, or fracture not explained by the level of trauma</p><p></p><p>By contrast, screening is not recommended for asymptomatic patients who are not members of a high-risk group, according to the United States Preventive Services Task Force [<a href="#rid8">8</a>]. Although broad screening might permit recognition and correction of subclinical nutritional deficiency states, resolution of mild symptoms, and, potentially, decreased risk for other complications [<a href="#rid9">9</a>], it is also proposed that asymptomatic individuals may have difficulty adhering to dietary treatment.</p><p class="headingAnchor" id="H477994579"><span class="h2">Members of high-risk groups</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to screen</strong> – We suggest screening all members of the following high-risk groups  (<a class="graphic graphic_table graphicRef50751" href="/z/d/graphic/50751.html" rel="external">table 1</a>), regardless of symptoms (see  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'High-risk groups'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>First-degree relatives of patients with celiac disease</p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune thyroiditis</p><p class="bulletIndent2"><span class="glyph">•</span>Type 1 diabetes</p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune liver disease</p><p class="bulletIndent2"><span class="glyph">•</span>Down syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Selective IgA deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Turner syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Williams syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Juvenile chronic arthritis</p><p></p><p class="bulletIndent1">This suggestion to screen asymptomatic individuals in these high-risk groups is consistent with several pediatric guidelines [<a href="#rid1">1,2,6</a>] but differs from guidelines used for adults in the United States, in which the recommendation is equivocal [<a href="#rid5">5,7</a>]. This difference in recommendations reflects a debate about the utility of screening for celiac disease among truly asymptomatic individuals belonging to a high-risk group because the benefit of treating such individuals has not been proven. Guidelines from the United Kingdom encourage testing for the first three of these high-risk groups and suggest consideration of testing for the other groups on this list, as well as for individuals with a variety of nonspecific symptoms [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Who should be tested'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Method of screening</strong> – If screening is undertaken for asymptomatic individuals in these high-risk groups, testing should first be performed at three years of age or older and on a gluten-containing diet for at least one year. If initial results are negative, screening tests should be repeated at intervals or at any time that symptoms develop. The optimal time interval for subsequent testing has not been studied, but, in our practice, we screen asymptomatic members of these groups approximately every three years during childhood or up to annually if other bloodwork is being obtained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncertainties</strong> – The debate continues about the utility of screening asymptomatic individuals in these high-risk groups and in the general population, and recommendations may change as new information arises about the potential risks and benefits of screening. As an example, evidence is conflicting regarding the balance of benefits and burdens of mass screening for celiac disease among children with type 1 diabetes. In a study of children with type 1 diabetes mellitus, those with asymptomatic celiac disease were slightly thinner (as indicated by a lower body mass index Z-score), but height, bone mineral density, and glycemic control were similar compared with matched controls [<a href="#rid11">11</a>]. Similarly, in a randomized trial of individuals with type 1 diabetes and celiac disease, a gluten-free diet resulted in no differences in outcomes after one year [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arguments against mass screening are that the burden of a gluten-free diet may negatively affect quality of life and may have few benefits for individuals with truly asymptomatic celiac disease. Moreover, there is a concern that mass screening programs may prompt self-diagnosis and self-treatment without medical oversight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arguments in favor of mass screening are that identifying apparently asymptomatic individuals may provide some benefits by improving subclinical signs and symptoms and preventing long-term complications [<a href="#rid13">13</a>]. Several studies suggest that having both celiac disease and type 1 diabetes is associated with a higher prevalence of microvascular complications and metabolic bone disease, suggesting that these two conditions may have additive complications [<a href="#rid14">14-16</a>]. (See  <a class="medical medical_review" href="/z/d/html/5823.html" rel="external">"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines recommend screening for celiac disease in these high-risk groups [<a href="#rid2">2</a>]. However, until the balance of benefits and burdens of mass screening for this population are better understood, it is reasonable to make screening and treatment decisions on a case-by-case basis, based on a collaborative discussion of estimated risks, symptoms, and treatment burden.</p><p></p><p class="headingAnchor" id="H477986526"><span class="h1">INITIAL SEROLOGIC TESTING</span><span class="headingEndMark"> — </span>The first step is to perform serologic testing. The serology results and level of clinical suspicion determine whether to move on to endoscopic biopsy  (<a class="graphic graphic_algorithm graphicRef101112" href="/z/d/graphic/101112.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H477986532"><span class="h2">Pretesting diet</span><span class="headingEndMark"> — </span>Testing should ideally be performed while on a gluten-containing diet because a gluten-free diet increases the risk of false-negative results. The pretesting diet should ideally include at least 3 g gluten per day (equivalent to approximately one slice of bread daily) for at least six weeks prior to testing.</p><p>If the child is already on a gluten-free diet prior to testing, it is reasonable to proceed with serologic testing. In this case, a positive result is valid and suggests celiac disease. However, if the results are negative, we suggest an attempt at a formal gluten rechallenge with at least 10 g gluten daily for 8 to 12 weeks before retesting  (<a class="graphic graphic_algorithm graphicRef139785" href="/z/d/graphic/139785.html" rel="external">algorithm 2</a>). The duration and amount of gluten required for diagnostic accuracy has not been fully established [<a href="#rid17">17</a>]. Serologies may become negative within weeks of beginning a gluten-free diet but may take up to two years or even longer in some cases [<a href="#rid18">18</a>]. A diagnostic approach for patients who are unwilling or unable to resume a gluten-containing diet before testing is outlined below. (See <a class="local">'Patients already on a gluten-free diet'</a> below.)</p><p>We do not recommend empiric initiation of a gluten-free diet, because the symptoms of celiac disease are nonspecific. Furthermore, a gluten-free diet is complex, expensive, and has far-reaching implications for the child's quality of life.</p><p class="headingAnchor" id="H477995188"><span class="h2">Tissue transglutaminase antibodies</span><span class="headingEndMark"> — </span>For most patients, the most valuable test is for IgA antibodies against tissue transglutaminase (tTG-IgA) [<a href="#rid5">5,19</a>]. Total IgA should also be measured (if not previously tested) to exclude IgA deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Next steps depend on the degree of tTG-IgA elevation and level of symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clearly elevated</strong> – If the results are ≥3 times the upper limit of normal (ULN), we proceed to endoscopy. If the results are strongly positive (≥10 times the ULN), we discuss the option of pursuing a serologic diagnosis, as outlined in European guidelines [<a href="#rid20">20</a>] and discussed below. (See <a class="local">'Subsequent evaluation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mildly elevated</strong> – If tTG-IgA antibodies are only mildly elevated (levels that are between 1 and 3 times the ULN), we proceed to endoscopy if the patient has clinically significant symptoms (eg, loose stools, frequent abdominal pain, and/or poor weight gain).</p><p></p><p class="bulletIndent2">If the patient has few or no symptoms or if the family is reluctant to proceed to endoscopy, we offer additional serologic testing with anti-endomysial antibodies (EMA):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If EMA is positive, the diagnosis of celiac disease is more likely and we suggest proceeding to endoscopy to confirm it. If the family is still reluctant to proceed to endoscopy, we advise continuing a gluten-containing diet and recheck tTG-IgA in six months. (See <a class="local">'Subsequent evaluation'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If EMA is negative, it is reasonable to defer doing a biopsy if the patient is asymptomatic because the chance of finding the characteristic histologic changes of celiac disease is relatively low. In this case, we observe the patient on a gluten-containing diet and repeat serologies in six months, or sooner if symptoms occur [<a href="#rid21">21</a>]. However, if serologies remain positive after one to two years, we usually proceed to endoscopy because celiac disease is occasionally found in individuals with mild elevations of tTG-IgA and negative EMA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal</strong> – If tTG-IgA antibodies are within the normal range, active celiac disease is unlikely. In this case, it is reasonable to observe the patient and repeat the test if symptoms develop or worsen. For patients who are members of a high-risk group (eg, children with type 1 diabetes or autoimmune thyroiditis), we repeat the test in approximately three years, or earlier if symptoms develop.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test characteristics</strong> – tTG-IgA is highly sensitive, specific, and more cost-effective than other antibody tests  (<a class="graphic graphic_table graphicRef75505" href="/z/d/graphic/75505.html" rel="external">table 3</a>). However, false-positive and false-negative results may still occur in populations with a low risk for celiac disease. The sensitivity and specificity of tTG-IgA antibodies for biopsy-proven celiac disease are generally above 96 percent, using second-generation enzyme-linked immunosorbent assays (ELISA) technology [<a href="#rid2">2,22,23</a>]. Sensitivities are reported to be lower in children younger than two years, although this is controversial [<a href="#rid24">24-26</a>] (see <a class="local">'Children younger than two years'</a> below). Rapid office-based test kits have somewhat lower sensitivity and specificity, so a laboratory-based assay is recommended in patients with positive results of the rapid test or those with negative results of the rapid test but strong clinical suspicion of celiac disease [<a href="#rid27">27,28</a>]. Limited evidence suggests that tTG-IgA antibodies may be falsely elevated during a febrile illness [<a href="#rid29">29</a>] or in patients with other autoimmune diseases and conditions [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H33166777"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Other serologic tests that are sometimes used to support the diagnosis of celiac disease include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EMA</strong> – EMA is typically used as a second-line test to clarify the diagnosis in patients with equivocal results of tTG-IgA, including asymptomatic members of a high-risk group. EMA is also included as one of the required criteria for a serologic diagnosis, according to European guidelines and described below [<a href="#rid1">1,19,31</a>]. (See <a class="local">'Nonbiopsy diagnosis (option for selected patients)'</a> below.)</p><p></p><p class="bulletIndent1">EMA is an immunofluorescence test for IgA antibodies to endomysium, a structure of the smooth muscle connective tissue [<a href="#rid32">32</a>]. It is more specific than tTG-IgA but is more expensive and somewhat dependent on operator interpretation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deamidated gliadin peptide (DGP)</strong> – DGP also has good diagnostic accuracy and may be particularly useful for young children. It is a second-generation antigliadin antibody test [<a href="#rid33">33-36</a>]. (See <a class="local">'Children younger than two years'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antireticulin antibodies</strong> – Tests of antireticulin antibodies have reasonably high specificity, but lower sensitivity, and are no longer used [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antigliadin antibodies</strong> – Standard (first-generation) IgA or IgG antigliadin antibodies are considerably less reliable and are not recommended [<a href="#rid5">5,38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human leukocyte antigen (HLA) testing</strong> – HLA testing has limited value in evaluating for celiac disease. Although virtually all individuals with celiac disease have either HLA-DQ2 or DQ8 haplotypes, this is also the case for approximately 40 percent of the general population [<a href="#rid2">2,27,40,41</a>]. Moreover, these HLA types are particularly common among members of groups at high risk for celiac disease (eg, first-degree relatives of patients with celiac disease or patients with autoimmune diseases). Thus, the presence of HLA-DQ2 or DQ8 is not informative, while the absence of these haplotypes essentially excludes celiac disease. HLA testing is no longer required for a nonbiopsy diagnosis [<a href="#rid1">1</a>]. (See <a class="local">'Nonbiopsy diagnosis (option for selected patients)'</a> below.)</p><p></p><p>Efforts are being made to define potential nonserologic biomarkers for celiac disease activity, which might be used as an index of the immune response to the gluten challenge [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H477995258"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Variations in the diagnostic approach outlined above are appropriate for the following populations:</p><p class="headingAnchor" id="H1400248565"><span class="h3">Children younger than two years</span><span class="headingEndMark"> — </span>For children younger than two years, tTG-IgA is the best initial test for IgA-sufficient children, as it is for older individuals, with &gt;97 percent sensitivity for detecting celiac disease [<a href="#rid43">43,44</a>]. Total IgA should be measured concurrently to exclude IgA deficiency. If the tTG-IgA is negative and there is a high clinical suspicion for celiac disease (or if the patient is IgA deficient), we suggest sequential testing with DGP-IgG to detect the few patients with positive DGP-IgG but normal tTG-IgA [<a href="#rid1">1</a>]. Although early studies raised the possibility that DGP-IgG may be more sensitive than tTG-IgA in this age group [<a href="#rid45">45,46</a>], subsequent studies indicate that tTG-IgA is at least as sensitive as DGP-IgG (except for patients with IgA deficiency) [<a href="#rid5">5,26,43,44</a>]. No serologic test is 100 percent sensitive, and, if there is strong clinical suspicion for celiac disease, biopsy should still be pursued even in the absence of positive serologies.</p><p class="headingAnchor" id="H4085390759"><span class="h3">Immunoglobulin A deficiency</span><span class="headingEndMark"> — </span>Approximately 2 percent of children with celiac disease will have previously unrecognized IgA deficiency. Conversely, approximately 8 percent of individuals with selective IgA deficiency have celiac disease (see  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"</a>). Because of this association, we measure total IgA as part of the initial testing for celiac disease (if not already done).</p><p>If total IgA is below the normal range (indicating IgA deficiency), the tTG-IgA test is invalid [<a href="#rid5">5</a>]. Instead, testing should be performed with IgG antibodies to tTG (tTG-IgG). Because tTG-IgG has limited specificity, we suggest concurrent measurement of DGP-IgG [<a href="#rid1">1</a>]. If one or both of these IgG-based tests is elevated, the patient should be further evaluated with an intestinal biopsy; a nonbiopsy diagnosis is not appropriate for this group of patients. (See <a class="local">'Subsequent evaluation'</a> below.)</p><p class="headingAnchor" id="H995685990"><span class="h3">Patients already on a gluten-free diet</span><span class="headingEndMark"> — </span>For patients who are already on a gluten-free diet, our first-line approach is to reintroduce moderate amounts of wheat into the diet before performing serologic testing, as described above  (<a class="graphic graphic_algorithm graphicRef139785" href="/z/d/graphic/139785.html" rel="external">algorithm 2</a>) [<a href="#rid20">20,47</a>]. (See <a class="local">'Pretesting diet'</a> above.)</p><p>For those who are unwilling to reintroduce gluten, we suggest serologic testing for tTG-IgA, with or without EMA. If these antibodies are elevated, an intestinal biopsy should be obtained to confirm the diagnosis of celiac disease. If these antibodies are not elevated, celiac disease is not excluded. In this case, we suggest HLA-DQ2/DQ8 testing to determine whether the patient is genetically susceptible to celiac disease [<a href="#rid5">5,19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient tests negative for HLA-DQ2/DQ8, celiac disease is essentially excluded. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Genetic factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient tests positive for HLA-DQ2/DQ8, a gluten challenge is needed to make a definitive diagnosis of celiac disease. In this case, we reintroduce gluten into the diet (10 g gluten per day), then retest for tTG-IgA after 8 to 12 weeks, or sooner if symptoms occur [<a href="#rid20">20,47</a>].</p><p></p><p>For children younger than five years who have negative antibody testing, we generally avoid a gluten challenge because they may not be able to verbalize symptoms. For these patients, we generally advise continuing the gluten-free diet until the child is at least five years of age, then proceeding to a gluten challenge if the family is willing to do so.</p><p class="headingAnchor" id="H2048871898"><span class="h3">Dermatitis herpetiformis</span><span class="headingEndMark"> — </span>Patients with dermatitis herpetiformis established by skin biopsy are presumed to have celiac disease and can be treated with a gluten-free diet without other diagnostic studies. However, a baseline measurement of tTG-IgA is valuable to monitor improvement after institution of a gluten-free diet. Dermatitis herpetiformis likely occurs more commonly than clinically recognized, with one study finding one case of dermatitis herpetiformis for every eight celiac disease patients [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Non-gastrointestinal manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis"</a>.)</p><p class="headingAnchor" id="H477986957"><span class="h1">SUBSEQUENT EVALUATION</span></p><p class="headingAnchor" id="H585046470"><span class="h2">Intestinal biopsy (most patients)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Individuals with positive IgA antibodies against tissue transglutaminase (tTG-IgA) or anti-endomysial antibodies (EMA) should undergo an intestinal biopsy to establish the diagnosis of celiac disease [<a href="#rid5">5</a>]. A possible exception is selected patients with very high tTG-IgA results and classic symptoms of celiac disease. (See <a class="local">'Nonbiopsy diagnosis (option for selected patients)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – The biopsy should be performed with the patient on a gluten-containing diet. Multiple biopsies should be taken (four from the distal duodenum and at least one from the duodenal bulb) because the disease may have a patchy distribution or initially be confined to the duodenal bulb [<a href="#rid5">5,49-53</a>]. Endoscopy and biopsy are also appropriate for patients with negative serologic testing if there is a strong clinical suspicion of celiac disease [<a href="#rid5">5</a>]. Capsule endoscopy should not be used as a substitute for endoscopy, because it is much less sensitive for detecting celiac disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – The intestinal histopathology should be interpreted by an expert pathologist. The histologic features of celiac disease are usually described using the Marsh classification  (<a class="graphic graphic_table graphicRef89797" href="/z/d/graphic/89797.html" rel="external">table 4</a> and <a class="graphic graphic_figure graphicRef60343" href="/z/d/graphic/60343.html" rel="external">figure 1</a>); they range from a mild alteration characterized only by increased intraepithelial lymphocytes (Marsh type 1 lesion) to a flat mucosa with total villous atrophy, intraepithelial lymphocytosis, enhanced epithelial apoptosis, and crypt hyperplasia (Marsh type 3 lesion)  (<a class="graphic graphic_picture graphicRef76680" href="/z/d/graphic/76680.html" rel="external">picture 2</a>) [<a href="#rid54">54-59</a>]. The Marsh type 4 lesion has the same histologic features seen in the type 3 lesion, except that the crypts are hypoplastic. A gradient of decreasing severity from the proximal to the distal small intestine is often observed, correlating with the higher proximal concentration of dietary gluten. The degree of the villous atrophy does not necessarily correlate with the severity of clinical symptoms, and sampling errors can occur due to some inhomogeneity of mucosal inflammation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abnormal findings</strong> – Patients with histologic findings consistent with celiac disease (Marsh type 2 or higher) are diagnosed with celiac disease and should be prescribed a gluten-free diet. Rarely, other disorders can cause similar histologic findings  (<a class="graphic graphic_table graphicRef60030" href="/z/d/graphic/60030.html" rel="external">table 5</a>). For patients with equivocal findings (eg, Marsh type 1 lesions), management decisions depend on the level of suspicion for celiac disease, including type and severity of symptoms and results of celiac-specific antibody tests.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal findings</strong> – Patients with positive tests for tTG-IgA or EMA but normal small bowel histopathology are considered to have potential celiac disease  (<a class="graphic graphic_table graphicRef95864" href="/z/d/graphic/95864.html" rel="external">table 6</a>) [<a href="#rid60">60</a>]. It is important that the evaluation of such patients include expert review of multiple intestinal biopsies since the histologic abnormalities can be patchy. In some cases in which the diagnosis of celiac disease is unclear, testing for human leukocyte antigen (HLA)-DQ2/DQ8 may be helpful because, if the result is negative, this essentially excludes the possibility of celiac disease [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2">In general, we suggest not treating patients with potential celiac disease with a gluten-free diet if they are asymptomatic. However, these patients should be carefully monitored for growth failure and other symptoms that might suggest active celiac disease and should be rebiopsied if symptoms develop or if antibody levels remain positive after several years on a gluten-containing diet. Decisions about whether to begin a gluten-free diet for patients with positive serologic tests but normal biopsy results should be made on a case-by-case basis with the family, after consideration of the patient's level of symptoms, appropriate exclusion of other causes of the symptoms, the burden of maintaining a gluten-free diet, and the adequacy of the biopsied tissue samples.</p><p></p><p class="bulletIndent2">The natural history of potential celiac disease was described in a long-term study from Italy that found that 43 percent of children with positive tTG and EMA antibodies but normal histopathology progressed to villous atrophy and subsequent diagnosis of celiac disease over 12 years [<a href="#rid61">61</a>]. These observations suggest that a substantial number of children with seropositivity (tTG and EMA) and normal histopathology can progress to celiac disease over time, while others have transient seropositivity.</p><p></p><p class="headingAnchor" id="H3807560709"><span class="h2">Nonbiopsy diagnosis (option for selected patients)</span><span class="headingEndMark"> — </span>For selected patients who meet serologic criteria, we offer the option of forgoing the endoscopy, after a full discussion with the patient and family including the considerations outlined below. This approach is based on guidelines from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [<a href="#rid1">1,62,63</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Criteria for nonbiopsy diagnosis</strong> – Diagnosis without an intestinal biopsy is an option for patients with the following characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>tTG-IgA &gt;10 times the upper limit of normal (ULN), <strong>and</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Positive EMA-IgA (must be from a separate blood draw)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence</strong> – Support for a nonbiopsy diagnosis in selected patients comes from three large case series that reported that more than 98 percent of symptomatic patients with very high tTG-IgA and positive EMA had intestinal biopsy results consistent with celiac disease [<a href="#rid21">21,64,65</a>]. In one of these studies, the combination of very high tTG-IgA and positive EMA had a sensitivity, specificity, and positive predictive value of 69.3, 96.8, and 99.6 percent, respectively [<a href="#rid64">64</a>]. If malabsorption symptoms (diarrhea, weight loss, poor weight gain, or iron deficiency anemia) were included, the specificity and positive predictive value rose to 100 percent. The need to include the second antibody test in this diagnostic approach has been questioned since adding EMA testing does not improve the positive predictive value [<a href="#rid66">66</a>]. HLA typing has also been suggested to add strength to the diagnosis (because celiac disease would be effectively excluded in any patient that does not have HLA types DQ2 or DQ8) but is no longer required, because the additional diagnostic value of HLA typing in this setting appears to be small [<a href="#rid1">1,64</a>]. Symptoms are also no longer required according to ESPGHAN criteria [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advantages of a biopsy-based diagnosis</strong> – It is important to recognize the potential value of including intestinal biopsy as part of the diagnostic process for all patients, including those with very high tTG antibodies. Histologic confirmation provides for maximal diagnostic certainty, which is important because of the lifelong burden of a gluten-free diet. In particular, the endoscopy permits evaluation for concurrent mucosal inflammation other than celiac disease, including eosinophilic esophagitis, <em>Helicobacter</em> <em>pylori</em>, and Crohn disease of the proximal small intestine [<a href="#rid67">67-69</a>]. Moreover, despite the high sensitivity estimates reported above, occasional false-positive results occur [<a href="#rid21">21,64,65</a>]. Finally, there are concerns about the quantitative variability and lack of standardization between commercially available serologic tests for celiac disease. These considerations should be discussed with the patient and family before deciding whether to proceed with intestinal biopsy to confirm the diagnosis before embarking on a gluten-free diet.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Not valid in</strong> <strong>IgA deficiency</strong> – Patients with IgA deficiency should always have a biopsy-based diagnosis, even if their tTG-<strong>IgG</strong> antibody test is very high, because IgG-based antibody tests have not been sufficiently validated as biomarkers of disease [<a href="#rid70">70</a>]. Moreover, tTG-IgG is not a reliable marker of response to a gluten-free diet.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncertain validity outside of Europe</strong> – These criteria for a nonbiopsy diagnosis are based on studies of European children and with specific tTG-IgA assays. These criteria have not been formally approved by the North American Society, in part because they have not been validated for the tTG-IgA assays that are commonly used in North America. However, a Canadian study suggests that this will also apply in North America, while accepting a slight degree of uncertainty [<a href="#rid21">21</a>]. These regional recommendations may also reflect different values and preferences regarding the tolerance for uncertainty versus the patient burden and cost of endoscopy [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H477996429"><span class="h1">DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy-based diagnosis</strong> – A diagnosis of celiac disease is made if the results of celiac-specific antibody testing and the intestinal biopsy are both abnormal. The diagnosis is reinforced when symptoms resolve subsequently on a gluten-free diet  (<a class="graphic graphic_algorithm graphicRef101112" href="/z/d/graphic/101112.html" rel="external">algorithm 1</a>). Serologic tests that revert from positive to negative on a gluten-free diet may be used as supportive evidence of the diagnosis and are particularly valuable in individuals with minimal symptoms [<a href="#rid72">72</a>]. Patients who do not demonstrate a robust serologic response to a gluten-free diet, or whose initial endoscopic biopsies are not typical for celiac disease based on the Marsh criteria, may require a second endoscopy with biopsy while on a gluten-free diet to clarify the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonbiopsy diagnosis</strong> – European society guidelines offer the option of an alternate approach to diagnosis for selected patients with very high results of serologic tests (IgA antibodies against tissue transglutaminase [tTG-IgA] &gt;10 times the upper limit of normal [ULN]) and a positive anti-endomysial antibody (EMA) obtained on a separate serum sample [<a href="#rid1">1</a>]. The diagnosis is reinforced if the serologic tests revert to normal and symptoms resolve on a gluten-free diet. Considerations relevant to the diagnostic approach for this group of patients are discussed above. (See <a class="local">'Nonbiopsy diagnosis (option for selected patients)'</a> above.)</p><p></p><p>Treatment of individuals with confirmed celiac disease consists of a lifelong gluten-free diet, which improves gastrointestinal symptoms as well as most of the non-gastrointestinal symptoms of celiac disease and may reduce the risk of long-term adverse health consequences. Patients with dermatitis herpetiformis confirmed by skin biopsy also should be treated with a gluten-free diet. Details of the gluten-free diet and monitoring are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">"Management of celiac disease in children"</a>.)</p><p>Note that symptom response to a gluten-free diet alone is <strong>not sufficient</strong> to diagnose celiac disease, because these features do not distinguish between celiac disease and "nonceliac gluten sensitivity," which is defined as dose-dependent intolerance to gluten-containing grains after exclusion of celiac disease or wheat allergy [<a href="#rid2">2,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Nonceliac gluten sensitivity'</a>.)</p><p class="headingAnchor" id="H481124515"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113964.html" rel="external">"Society guideline links: Celiac disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/130048.html" rel="external">"Society guideline links: Dermatitis herpetiformis"</a>.)</p><p class="headingAnchor" id="H477987337"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15378.html" rel="external">"Patient education: Celiac disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1212.html" rel="external">"Patient education: Celiac disease in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H477987476"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children with suggestive symptoms</strong> – Serologic testing for celiac disease should be performed for children who present with findings consistent with classic celiac disease, which include persistent diarrhea, chronic constipation, recurrent abdominal pain, and failure to thrive, as well as for those who present with a dermatitis herpetiformis-type rash  (<a class="graphic graphic_picture graphicRef70783 graphicRef139241" href="/z/d/graphic/70783.html" rel="external">picture 1A-B</a>). Testing is also appropriate for children who present with other associated non-gastrointestinal symptoms  (<a class="graphic graphic_table graphicRef76474" href="/z/d/graphic/76474.html" rel="external">table 2A</a>), in whom no other underlying cause can be identified. (See <a class="local">'Patients with symptoms suggesting celiac disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children in high-risk groups</strong> – We also suggest testing asymptomatic individuals with the following characteristics, which are associated with an increased risk for celiac disease: first-degree relatives of patients with celiac disease and children with autoimmune thyroiditis, type 1 diabetes, autoimmune liver disease, juvenile chronic arthritis, Down syndrome, Turner syndrome, Williams syndrome, or selective IgA deficiency (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Members of high-risk groups'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid premature initiation of a gluten-free diet</strong> – A gluten-free diet should <strong>not</strong> be started prior to a full evaluation for celiac disease. This is because the symptoms of celiac disease are nonspecific and both antibody testing and intestinal biopsy results are only valid if they are performed while the patient is exposed to gluten. Moreover, a clinical response to a gluten-free diet is not sufficient to establish the diagnosis of celiac disease versus nonceliac gluten sensitivity. (See <a class="local">'Pretesting diet'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How to test</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serology</strong> – Serologic testing is performed by measuring one of several antibodies that are specific for celiac disease, with the patient on a gluten-containing diet  (<a class="graphic graphic_table graphicRef75505" href="/z/d/graphic/75505.html" rel="external">table 3</a>). The most clinically useful test is for IgA antibodies against tissue transglutaminase (tTG-IgA), which is highly sensitive, specific, and more cost-effective than other antibody tests. (See <a class="local">'Tissue transglutaminase antibodies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intestinal biopsy</strong> – Most patients with positive results of the serologic testing should undergo endoscopy, with biopsies from several areas of the duodenum including the duodenal bulb  (<a class="graphic graphic_algorithm graphicRef101112" href="/z/d/graphic/101112.html" rel="external">algorithm 1</a>). The histologic features of celiac disease range from a mild alteration characterized only by increased intraepithelial lymphocytes (Marsh type 1 lesion) to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis, and crypt hyperplasia (Marsh type 3 lesion)  (<a class="graphic graphic_figure graphicRef60343" href="/z/d/graphic/60343.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef76680" href="/z/d/graphic/76680.html" rel="external">picture 2</a>). (See <a class="local">'Intestinal biopsy (most patients)'</a> above.)</p><p></p><p class="bulletIndent2">Intestinal biopsy is valuable for all patients to achieve maximal diagnostic certainty and exclude other gastrointestinal diseases (eg, eosinophilic esophagitis). However, the biopsy is considered optional for selected patients with very high levels of tTG-IgA, positive anti-endomysial antibodies (EMA), and typical symptoms. For patients with these characteristics, the decision whether to perform endoscopy and biopsy should be made collaboratively with the patient and family. (See <a class="local">'Nonbiopsy diagnosis (option for selected patients)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Celiac disease</strong> – A diagnosis of celiac disease is made if the results of celiac-specific antibody testing and the intestinal biopsy are both abnormal. The diagnosis is reinforced when symptoms resolve subsequently on a gluten-free diet. Serologic tests that revert from positive to negative on a gluten-free diet may be used as supportive evidence of the diagnosis and are particularly valuable in individuals with minimal symptoms. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Potential" celiac disease</strong> – "Potential" celiac disease refers to patients who have positive serologic tests for celiac disease (tTG-IgA or EMA) but have normal small bowel histopathology. A gluten-free diet is not necessary in such patients if they are asymptomatic. However, it is important to ensure that the evaluation included multiple intestinal biopsies since histologic abnormalities can be patchy. These patients should be carefully monitored for growth failure and other symptoms that might suggest active celiac disease, and they should be rebiopsied if symptoms develop. (See <a class="local">'Intestinal biopsy (most patients)'</a> above and  <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">"Management of celiac disease in children", section on 'Potential celiac disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Implementation of a gluten-free diet and other details of treatment and monitoring of children with established celiac disease are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">"Management of celiac disease in children"</a>.)</p><p></p><p class="headingAnchor" id="H2560737044"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ivor D Hill, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Husby S, Koletzko S, Korponay-Szabó I, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr 2020; 70:141.</a></li><li><a class="nounderline abstract_t">Hill ID, Fasano A, Guandalini S, et al. NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders. J Pediatr Gastroenterol Nutr 2016; 63:156.</a></li><li><a class="nounderline abstract_t">AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.</a></li><li class="breakAll">National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: http://consensus.nih.gov/ (Accessed on March 11, 2011).</li><li><a class="nounderline abstract_t">Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Am J Gastroenterol 2023; 118:59.</a></li><li><a class="nounderline abstract_t">Fasano A, Araya M, Bhatnagar S, et al. Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition consensus report on celiac disease. J Pediatr Gastroenterol Nutr 2008; 47:214.</a></li><li><a class="nounderline abstract_t">Husby S, Murray JA, Katzka DA. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. Gastroenterology 2019; 156:885.</a></li><li><a class="nounderline abstract_t">Chou R, Bougatsos C, Blazina I, et al. Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317:1258.</a></li><li><a class="nounderline abstract_t">Kivelä L, Kaukinen K, Huhtala H, et al. At-Risk Screened Children with Celiac Disease are Comparable in Disease Severity and Dietary Adherence to Those Found because of Clinical Suspicion: A Large Cohort Study. J Pediatr 2017; 183:115.</a></li><li><a class="nounderline abstract_t">Downey L, Houten R, Murch S, et al. Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance. BMJ 2015; 351:h4513.</a></li><li><a class="nounderline abstract_t">Simmons JH, Klingensmith GJ, McFann K, et al. Impact of celiac autoimmunity on children with type 1 diabetes. J Pediatr 2007; 150:461.</a></li><li><a class="nounderline abstract_t">Mahmud FH, Clarke ABM, Joachim KC, et al. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care 2020; 43:1553.</a></li><li><a class="nounderline abstract_t">Stahl MG, Geno Rasmussen C, Dong F, et al. Mass Screening for Celiac Disease: The Autoimmunity Screening for Kids Study. Am J Gastroenterol 2021; 116:180.</a></li><li><a class="nounderline abstract_t">Leeds JS, Hopper AD, Hadjivassiliou M, et al. High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. Diabetes Care 2011; 34:2158.</a></li><li><a class="nounderline abstract_t">Rohrer TR, Wolf J, Liptay S, et al. Microvascular Complications in Childhood-Onset Type 1 Diabetes and Celiac Disease: A Multicenter Longitudinal Analysis of 56,514 Patients From the German-Austrian DPV Database. Diabetes Care 2015; 38:801.</a></li><li><a class="nounderline abstract_t">Simmons KM, McFann K, Taki I, et al. Reduced Bone Mineral Density Is Associated with Celiac Disease Autoimmunity in Children with Type 1 Diabetes. J Pediatr 2016; 169:44.</a></li><li><a class="nounderline abstract_t">Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62:996.</a></li><li><a class="nounderline abstract_t">Isaac DM, Rajani S, Yaskina M, et al. Antitissue Transglutaminase Normalization Postdiagnosis in Children With Celiac Disease. J Pediatr Gastroenterol Nutr 2017; 65:195.</a></li><li><a class="nounderline abstract_t">Snyder J, Butzner JD, DeFelice AR, et al. Evidence-Informed Expert Recommendations for the Management of Celiac Disease in Children. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:136.</a></li><li><a class="nounderline abstract_t">Gidrewicz D, Potter K, Trevenen CL, et al. Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population. Am J Gastroenterol 2015; 110:760.</a></li><li><a class="nounderline abstract_t">Troncone R, Maurano F, Rossi M, et al. IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease. J Pediatr 1999; 134:166.</a></li><li><a class="nounderline abstract_t">Basso D, Guariso G, Fasolo M, et al. A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies. J Pediatr Gastroenterol Nutr 2006; 43:613.</a></li><li><a class="nounderline abstract_t">Maglio M, Tosco A, Paparo F, et al. Serum and intestinal celiac disease-associated antibodies in children with celiac disease younger than 2 years of age. J Pediatr Gastroenterol Nutr 2010; 50:43.</a></li><li><a class="nounderline abstract_t">Panetta F, Torre G, Colistro F, et al. Clinical accuracy of anti-tissue transglutaminase as screening test for celiac disease under 2 years. Acta Paediatr 2011; 100:728.</a></li><li><a class="nounderline abstract_t">Catassi GN, Pulvirenti A, Monachesi C, et al. Diagnostic Accuracy of IgA Anti-Transglutaminase and IgG Anti-Deamidated Gliadin for Diagnosis of Celiac Disease in Children under Two Years of Age: A Systematic Review and Meta-Analysis. Nutrients 2021; 14.</a></li><li><a class="nounderline abstract_t">Hadithi M, von Blomberg BM, Crusius JB, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007; 147:294.</a></li><li><a class="nounderline abstract_t">Korponay-Szabó IR, Szabados K, Pusztai J, et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ 2007; 335:1244.</a></li><li><a class="nounderline abstract_t">De Leo L, Quaglia S, Ziberna F, et al. Serum anti-tissue transglutaminase antibodies detected during febrile illness may not be produced by the intestinal mucosa. J Pediatr 2015; 166:761.</a></li><li><a class="nounderline abstract_t">Castillo NE, Theethira TG, Leffler DA. The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf) 2015; 3:3.</a></li><li><a class="nounderline abstract_t">Rashtak S, Ettore MW, Homburger HA, Murray JA. Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther 2008; 28:805.</a></li><li><a class="nounderline abstract_t">Pittschieler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Paediatr Suppl 1996; 412:42.</a></li><li><a class="nounderline abstract_t">Prause C, Ritter M, Probst C, et al. Antibodies against deamidated gliadin as new and accurate biomarkers of childhood coeliac disease. J Pediatr Gastroenterol Nutr 2009; 49:52.</a></li><li><a class="nounderline abstract_t">Vermeersch P, Geboes K, Mariën G, et al. Diagnostic performance of IgG anti-deamidated gliadin peptide antibody assays is comparable to IgA anti-tTG in celiac disease. Clin Chim Acta 2010; 411:931.</a></li><li><a class="nounderline abstract_t">Rashtak S, Ettore MW, Homburger HA, Murray JA. Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol 2008; 6:426.</a></li><li><a class="nounderline abstract_t">Lammi A, Arikoski P, Simell S, et al. Antibodies to deamidated gliadin peptide in diagnosis of celiac disease in children. J Pediatr Gastroenterol Nutr 2015; 60:626.</a></li><li><a class="nounderline abstract_t">Ghedira I, Sghiri R, Ayadi A, et al. [Anti-endomysium, anti-reticulin and anti-gliadin antibodies, value in the diagnosis of celiac disease in the child]. Pathol Biol (Paris) 2001; 49:47.</a></li><li><a class="nounderline abstract_t">Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005; 128:S25.</a></li><li><a class="nounderline abstract_t">Richter T, Bossuyt X, Vermeersch P, et al. Determination of IgG and IgA antibodies against native gliadin is not helpful for the diagnosis of coeliac disease in children up to 2 years old. J Pediatr Gastroenterol Nutr 2012; 55:21.</a></li><li><a class="nounderline abstract_t">Kårhus LL, Thuesen BH, Skaaby T, et al. The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population. United European Gastroenterol J 2018; 6:866.</a></li><li><a class="nounderline abstract_t">DiGiacomo D, Santonicola A, Zingone F, et al. Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases. World J Gastroenterol 2013; 19:2507.</a></li><li><a class="nounderline abstract_t">Leonard MM, Silvester JA, Leffler D, et al. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology 2021; 160:720.</a></li><li><a class="nounderline abstract_t">Frulio G, Polimeno A, Palmieri D, et al. Evaluating diagnostic accuracy of anti-tissue Transglutaminase IgA antibodies as first screening for Celiac Disease in very young children. Clin Chim Acta 2015; 446:237.</a></li><li><a class="nounderline abstract_t">Khan MR, Silvester JA, Sparks B, et al. The Utility of IgA-Based Serologic Markers in Diagnosing Celiac Disease in Children 24 Months of Age or Younger. J Pediatr 2020; 224:158.</a></li><li><a class="nounderline abstract_t">Mubarak A, Gmelig-Meyling FH, Wolters VM, et al. Immunoglobulin G antibodies against deamidated-gliadin-peptides outperform anti-endomysium and tissue transglutaminase antibodies in children &lt;2 years age. APMIS 2011; 119:894.</a></li><li><a class="nounderline abstract_t">Barbato M, Maiella G, Di Camillo C, et al. The anti-deamidated gliadin peptide antibodies unmask celiac disease in small children with chronic diarrhoea. Dig Liver Dis 2011; 43:465.</a></li><li><a class="nounderline abstract_t">Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.</a></li><li><a class="nounderline abstract_t">Persechino F, Galli G, Persechino S, et al. Skin Manifestations and Coeliac Disease in Paediatric Population. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Bonamico M, Mariani P, Thanasi E, et al. Patchy villous atrophy of the duodenum in childhood celiac disease. J Pediatr Gastroenterol Nutr 2004; 38:204.</a></li><li><a class="nounderline abstract_t">Vogelsang H, Hänel S, Steiner B, Oberhuber G. Diagnostic duodenal bulb biopsy in celiac disease. Endoscopy 2001; 33:336.</a></li><li><a class="nounderline abstract_t">Bonamico M, Thanasi E, Mariani P, et al. Duodenal bulb biopsies in celiac disease: a multicenter study. J Pediatr Gastroenterol Nutr 2008; 47:618.</a></li><li><a class="nounderline abstract_t">Levinson-Castiel R, Hartman C, Morgenstern S, et al. The role of duodenal bulb biopsy in the diagnosis of celiac disease in children. J Clin Gastroenterol 2011; 45:26.</a></li><li><a class="nounderline abstract_t">Ofei S, Boyle B, Ediger T, Hill I. Adherence to Endoscopy Biopsy Guidelines for Celiac Disease. J Pediatr Gastroenterol Nutr 2015; 61:440.</a></li><li><a class="nounderline abstract_t">RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC Jr. Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue. Gastroenterology 1960; 38:28.</a></li><li><a class="nounderline abstract_t">Fry L, Seah PP, McMinn RM, Hoffbrand AV. Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. Br Med J 1972; 3:371.</a></li><li><a class="nounderline abstract_t">Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330.</a></li><li><a class="nounderline abstract_t">Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995; 9:273.</a></li><li><a class="nounderline abstract_t">Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential. Gut 1993; 34:150.</a></li><li><a class="nounderline abstract_t">Troncone R, Greco L, Mayer M, et al. Latent and potential coeliac disease. Acta Paediatr Suppl 1996; 412:10.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43.</a></li><li><a class="nounderline abstract_t">Auricchio R, Mandile R, Del Vecchio MR, et al. Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture. Gastroenterology 2019; 157:413.</a></li><li><a class="nounderline abstract_t">Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child 2013; 98:806.</a></li><li><a class="nounderline abstract_t">Kurppa K, Salminiemi J, Ukkola A, et al. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. J Pediatr Gastroenterol Nutr 2012; 54:387.</a></li><li><a class="nounderline abstract_t">Werkstetter KJ, Korponay-Szabó IR, Popp A, et al. Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice. Gastroenterology 2017; 153:924.</a></li><li><a class="nounderline abstract_t">Donat E, Ramos JM, Sánchez-Valverde F, et al. ESPGHAN 2012 Guidelines for Coeliac Disease Diagnosis: Validation Through a Retrospective Spanish Multicentric Study. J Pediatr Gastroenterol Nutr 2016; 62:284.</a></li><li><a class="nounderline abstract_t">Wolf J, Petroff D, Richter T, et al. Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy. Gastroenterology 2017; 153:410.</a></li><li><a class="nounderline abstract_t">Stewart MJ, Shaffer E, Urbanski SJ, et al. The association between celiac disease and eosinophilic esophagitis in children and adults. BMC Gastroenterol 2013; 13:96.</a></li><li><a class="nounderline abstract_t">Aydogdu S, Cakir M, Yuksekkaya HA, et al. Helicobacter pylori infection in children with celiac disease. Scand J Gastroenterol 2008; 43:1088.</a></li><li><a class="nounderline abstract_t">Virta LJ, Kolho KL. The risk of contracting pediatric inflammatory bowel disease in children with celiac disease, epilepsy, juvenile arthritis and type 1 diabetes--a nationwide study. J Crohns Colitis 2013; 7:53.</a></li><li><a class="nounderline abstract_t">López RV, Cid CM, García GR, et al. Influence of the 2012 European Guidelines in Diagnosis and Follow-up of Coeliac Children With Selective IgA Deficiency. J Pediatr Gastroenterol Nutr 2020; 71:59.</a></li><li><a class="nounderline abstract_t">Badizadegan K, Vanlandingham DM, Hampton W, Thompson KM. Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America. BMC Health Serv Res 2020; 20:962.</a></li><li><a class="nounderline abstract_t">Bannister EG, Cameron DJ, Ng J, et al. Can celiac serology alone be used as a marker of duodenal mucosal recovery in children with celiac disease on a gluten-free diet? Am J Gastroenterol 2014; 109:1478.</a></li></ol></div><div id="topicVersionRevision">Topic 100553 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31568151" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27035374" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17087935" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17087935" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36602836" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664878" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition consensus report on celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578783" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28350935" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28153477" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : At-Risk Screened Children with Celiac Disease are Comparable in Disease Severity and Dietary Adherence to Those Found because of Clinical Suspicion: A Large Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26333593" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452216" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Impact of celiac autoimmunity on children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345653" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701732" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mass Screening for Celiac Disease: The Autoimmunity Screening for Kids Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911773" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25690004" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microvascular Complications in Childhood-Onset Type 1 Diabetes and Celiac Disease: A Multicenter Longitudinal Analysis of 56,514 Patients From the German-Austrian DPV Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561381" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduced Bone Mineral Density Is Associated with Celiac Disease Autoimmunity in Children with Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22619366" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27906802" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antitissue Transglutaminase Normalization Postdiagnosis in Children With Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565547" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence-Informed Expert Recommendations for the Management of Celiac Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22197856" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25823767" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931524" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130737" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19934769" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum and intestinal celiac disease-associated antibodies in children with celiac disease younger than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21166861" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical accuracy of anti-tissue transglutaminase as screening test for celiac disease under 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35010880" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnostic Accuracy of IgA Anti-Transglutaminase and IgG Anti-Deamidated Gliadin for Diagnosis of Celiac Disease in Children under Two Years of Age: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063612" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25722272" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serum anti-tissue transglutaminase antibodies detected during febrile illness may not be produced by the intestinal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326000" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The present and the future in the diagnosis and management of celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19145736" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783755" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Coeliac disease: screened by a new strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465869" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antibodies against deamidated gliadin as new and accurate biomarkers of childhood coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171961" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic performance of IgG anti-deamidated gliadin peptide antibody assays is comparable to IgA anti-tTG in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18304884" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25522308" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antibodies to deamidated gliadin peptide in diagnosis of celiac disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11265223" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : [Anti-endomysium, anti-reticulin and anti-gliadin antibodies, value in the diagnosis of celiac disease in the child].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825123" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249805" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Determination of IgG and IgA antibodies against native gliadin is not helpful for the diagnosis of coeliac disease in children up to 2 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30023064" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23674852" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33130104" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944768" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evaluating diagnostic accuracy of anti-tissue Transglutaminase IgA antibodies as first screening for Celiac Disease in very young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32593411" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Utility of IgA-Based Serologic Markers in Diagnosing Celiac Disease in Children 24 Months of Age or Younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085366" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunoglobulin G antibodies against deamidated-gliadin-peptides outperform anti-endomysium and tissue transglutaminase antibodies in children&lt;2 years age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257356" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The anti-deamidated gliadin peptide antibodies unmask celiac disease in small children with chronic diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625418" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34684612" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Skin Manifestations and Coeliac Disease in Paediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734885" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Patchy villous atrophy of the duodenum in childhood celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11315895" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnostic duodenal bulb biopsy in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18979585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Duodenal bulb biopsies in celiac disease: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628309" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The role of duodenal bulb biopsy in the diagnosis of celiac disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944219" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adherence to Endoscopy Biopsy Guidelines for Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14439871" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5070159" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727768" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue').</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7549028" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Morphology of the mucosal lesion in gluten sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432463" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783748" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Latent and potential coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22345659" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Oslo definitions for coeliac disease and related terms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978358" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23986560" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22094901" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624578" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26020370" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : ESPGHAN 2012 Guidelines for Coeliac Disease Diagnosis: Validation Through a Retrospective Spanish Multicentric Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461188" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23721294" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The association between celiac disease and eosinophilic esophagitis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18609161" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Helicobacter pylori infection in children with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445838" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The risk of contracting pediatric inflammatory bowel disease in children with celiac disease, epilepsy, juvenile arthritis and type 1 diabetes--a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044834" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Influence of the 2012 European Guidelines in Diagnosis and Follow-up of Coeliac Children With Selective IgA Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33081760" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070050" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Can celiac serology alone be used as a marker of duodenal mucosal recovery in children with celiac disease on a gluten-free diet?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
